John G. Rizk

1.6k total citations · 1 hit paper
32 papers, 1.0k citations indexed

About

John G. Rizk is a scholar working on Infectious Diseases, Epidemiology and Neurology. According to data from OpenAlex, John G. Rizk has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 9 papers in Epidemiology and 6 papers in Neurology. Recurrent topics in John G. Rizk's work include COVID-19 Clinical Research Studies (10 papers), Long-Term Effects of COVID-19 (6 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). John G. Rizk is often cited by papers focused on COVID-19 Clinical Research Studies (10 papers), Long-Term Effects of COVID-19 (6 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). John G. Rizk collaborates with scholars based in United States, Lebanon and Italy. John G. Rizk's co-authors include Youssef Rizk, Donald N. Forthal, Brandon Michael Henry, Giuseppe Lippi, Carl J. Lavie, Kamyar Kalantar‐Zadeh, Mandeep R. Mehra, Rania M. El-Lababidi, John C. Lewin and Partha Sardar and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Drugs.

In The Last Decade

John G. Rizk

28 papers receiving 975 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention and Treatment of Monkeypox

2022 410 citations John G. Rizk, Giuseppe Lippi et al. Drugs profile →

Peers

Countries citing papers authored by John G. Rizk

Since Specialization

Citations

This map shows the geographic impact of John G. Rizk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John G. Rizk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John G. Rizk more than expected).

Fields of papers citing papers by John G. Rizk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John G. Rizk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John G. Rizk. The network helps show where John G. Rizk may publish in the future.

Co-authorship network of co-authors of John G. Rizk

This figure shows the co-authorship network connecting the top 25 collaborators of John G. Rizk. A scholar is included among the top collaborators of John G. Rizk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John G. Rizk. John G. Rizk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	Drugs	Youssef Rizk, Giuseppe Lippi et al.	13
2	County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities	PLoS ONE	John G. Rizk, Danya M. Qato et al.	2
3	COVID-19, influenza A H5N1, monkeypox (mpox): is laboratory medicine ready for the next pandemic?	Journal of Laboratory and Precision Medicine	Giuseppe Lippi, John G. Rizk	2
4	Impact of manufacturer-initiated list price reduction on patient out-of-pocket costs for PCSK9 inhibitors	Journal of Managed Care & Specialty Pharmacy	John G. Rizk, T. Joseph Mattingly et al.	1
5	Managing Monkeypox Virus Infections: A Contemporary Review.	SHILAP Revista de lepidopterología	John G. Rizk, Nasibeh Roozbeh et al.	5
6	Triglycerides and Renal Outcomes According to Albuminuria and in Consideration of Other Metabolic Syndrome Components in Diabetic US Veterans	American Journal of Nephrology	John G. Rizk, Jui‐Ting Hsiung et al.	3
7	Prevention and Treatment of Monkeypox breakdown →	Drugs	John G. Rizk, Giuseppe Lippi et al.	410
8	FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps	BMJ evidence-based medicine	John G. Rizk, John C. Lewin	2
9	County-Level COVID-19 Vaccination Rates, Non-Communicable Diseases, and Socioeconomic Inequities: Applying Syndemic Theory to Vaccines	Journal of Health Care for the Poor and Underserved	John G. Rizk, Fadia T. Shaya	0
10	Serum Creatinine-to-Cystatin-C Ratio as a Potential Muscle Mass Surrogate and Racial Differences in Mortality	Journal of Renal Nutrition	John G. Rizk, Elani Streja et al.	16
11	Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19	Drugs	John G. Rizk, Diana Tran et al.	11
12	Thromboprophylaxis in outpatients with COVID-19: a safe bet or tilting at windmills?	Minerva Cardiology and Angiology	John G. Rizk, Giuseppe Lippi et al.	3
13	The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action	Vaccine	John G. Rizk, Charles E. Barr et al.	9
14	Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients	Reviews in Endocrine and Metabolic Disorders	John G. Rizk, Steven Gabardi et al.	8
15	Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis	JAMA Cardiology	John G. Rizk, Partha Sardar et al.	81
16	Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.	Drug Discovery Today	John G. Rizk, Donald N. Forthal et al.	50
17	Anticoagulation management strategies in heart transplantation	Progress in Cardiovascular Diseases	John G. Rizk, Mandeep R. Mehra	11
18	Pharmaco-Immunomodulatory Therapy in COVID-19	Drugs	John G. Rizk, Kamyar Kalantar‐Zadeh et al.	202
19	Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review	The Clinical Respiratory Journal	John G. Rizk et al.	1
20	An Introduction to human rights in the Middle East & North Africa - a guide for NGOs		M. Moynihan, John G. Rizk et al.	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact